Cardiotoxicity not only impacts the efficacy of drugs but can also lead to severe cardiovascular events, potentially endangering patients' lives. Therefore, Creative Biolabs has developed efficient and reliable animal models for in-depth analysis of cardiotoxicity. We can assist clients in forecasting the lead candidate's safety, evaluating their mechanisms, and optimizing project design.

Introduction

Cardiotoxicity can lead to serious health issues such as arrhythmias and heart failure, assessing a drug candidate's potential cardiac toxicity is a crucial step in the drug development process. By utilizing animal models, Creative Biolabs can thoroughly investigate the mechanisms by which drugs affect the heart under both physiological and pathological conditions. Our animal models not only facilitate the identification of drugs with a high safety profile but also help recognize potential cardiac adverse effects early on, thereby mitigating risks in later clinical trials.

Furthermore, we provide clients with customized and controllable experimental environments that effectively simulate human heart functions and responses, allowing for the optimization of drug formulations and administration strategies. Till now, our cardiotoxic animal modeling offers significant support for fundamental research, enabling our clients to gain a more comprehensive understanding of the mechanisms underlying heart diseases and their interactions with various leads.

Fig.1 Cardiotoxicity Mechanisms Analysis.^1,3

Services

Creative Biolabs boasts a team of experts from various fields including drug development, toxicology, and animal experimentation. Our team members possess extensive experience and are equipped to design and implement suitable animal modeling strategies tailored to client needs, including the selection of appropriate animal species (such as mice, rabbits, and pigs), as well as the identification of suitable drug dosages and administration methods.

STEP1: Selection of Appropriate Animal Models:

Commonly used animal models include mice, rats, rabbits, and dogs. When making a choice, it's important to consider the physiological similarities between these animals and humans.

Recently, transgenic animals and humanized mouse models have gained attention for their ability to better mimic human cardiac toxicity.

STEP2: Establishment of Cardiotoxicity Assessment Criteria:

Frequently used indicators comprise heart rate, electrocardiogram (ECG) variations, and pathological examination of cardiac tissues.

Researchers can utilize biomarkers and gene expression analysis as methods for toxicity evaluation.

STEP3: Drug Administration Routes and Dosage Selection:

The appropriate selection of administration routes (such as oral or intravenous) and dosages is crucial for toxicity assessment.

It's essential to consider the pharmacokinetic properties of the drug to accurately replicate clinical scenarios for oral or intravenous administration.

STEP4: Dynamic Monitoring and Data Analysis:

Real-time monitoring of cardiac function (using echocardiography and continuous ECG monitoring) and tissue changes is vital.

Bioinformatics and statistical methodologies should be applied to analyze experimental results, allowing for reliable conclusions.

STEP5: Long-term Observation and Follow-up:

Conducting long-term observations is key to assessing potential chronic toxicity and the recovery process.

Fig.2 Lipid Nanomedicines as Potential Therapeutic Agents for Reducing Cardiotoxicity.^2,3

Features

• Diversity in Species Selection: Depending on research requirements, various animal models such as mice, rats, rabbits, dogs, and pigs can be chosen to mimic human cardiac physiology and pathology.
• Controlled Experimental Conditions: Animal models enable us to meticulously control experimental variables, such as routes of administration, dosages, timing, and environmental factors, thus minimizing extraneous influences.
• Physiological Parameter Monitoring: Advanced monitoring technologies, such as electrocardiograms and echocardiograms, provide real-time assessments of cardiac function, allowing for the collection of detailed physiological data.
• Application of Genetic Modification Techniques: Gene-editing techniques can be used to develop specific transgenic animal models that simulate particular genetic disorders or drug responses.
• Variety of Cardiotoxicity Assessment Methods: A comprehensive evaluation of cardiotoxicity is achieved by integrating methodologies from physiology, pathology, and molecular biology levels.
• High-Throughput Screening Capability: By establishing multiple models, we can rapidly screen the cardiotoxic effects of various drugs or compounds, providing early data support for drug development.
• Effective Mechanistic Exploration: Our animal models serve as a novel platform for investigating the specific biological mechanisms underlying cardiotoxicity, helping to clarify the signaling pathways and molecular mechanisms involved in toxic effects.

Creative Biolabs offers services for the creation of animal models based on cardiac toxicity analysis. Utilizing cutting-edge bioinformatics and high-throughput screening techniques, along with the latest cardiac toxicity biomarkers, we provide comprehensive assessments of drug-related cardiac toxicity risks. Whether your focus is on mice, rabbits, or guinea pigs, we can select the most suitable model according to the characteristics of your drug and your research objectives, ensuring the reliability and applicability of experimental results. If you are looking to deepen your understanding of cardiac toxicity or need robust animal models to support your studies, please feel free to contact us.

References

1. Rybchenko, Vladislav S., et al. "Targeted cytokine delivery for cancer treatment: engineering and biological effects." Pharmaceutics 15.2 (2023): 336.
2. Setia, Aseem, et al. "Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity." Nanotheranostics 8.4 (2024): 473.
3. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use